Abstract
Nano-drug delivery systems (NDDS) for colon-targeted drug delivery are an active area of research on local diseases affecting the colon, such as ulcerative colitis, Crohn’s disease, colon cancer, and for the delivery of peptide or protein drugs and vaccinations. In particular, targeted nano-drug delivery to the colon is advantageous for colon-specific diseases because nanoparticles can accumulate in diseased parts, improve the efficacies of therapeutics, and enable localized treatments, which reduces systemic toxicity. However, there are many hurdles, such as burst drug release, enzyme and acidic degradation of drug and carrier in the stomach, pH variations, mucus entrapment, and systemic uptake in the upper small intestine, which could challenge and compromise the successful delivery of NDDS to the colon. With advancements in NDDS, it may be possible to overcome these challenges leading to efficient drug delivery for colon-specific disorders. This review describes a few of the potential colon-specific drug delivery areas and the challenges faced by colon-targeted orally administered delivery systems, and provides an updated summary of recent advances in the development of orally administered NDDS for colon targeting, and the future advances in this research.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdelmegid AM, Abdo FK, Ahmed FE, Kattaia AAA (2019) Therapeutic effect of gold nanoparticles on DSS-induced ulcerative colitis in mice with reference to interleukin-17 expression. Sci Rep 9:10176. https://doi.org/10.1038/s41598-019-46671-1
Ali H, Weigmann B, Neurath MF, Collnot EM, Windbergs M, Lehr CM (2014) Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J Control Release 183:167–177. https://doi.org/10.1016/j.jconrel.2014.03.039
Amidon S, Brown JE, Dave VS (2015) Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech 16:731–741. https://doi.org/10.1208/s12249-015-0350-9
Ashford M, Fell JT, Attwood D, Sharma H, Woodhead PJ (1993) An in vivo investigation into the suitability of pH dependent polymers for colonic targeting. Int J Pharm 95:193–199. https://doi.org/10.1016/0378-5173(93)90406-6
Banerjee A, Qi J, Gogoi R, Wong J, Mitragotri S (2016) Role of nanoparticle size, shape and surface chemistry in oral drug delivery. J Control Release 238:176–185. https://doi.org/10.1016/j.jconrel.2016.07.051
Banerjee A, Pathak S, Subramanium VD, Murugesan R, Verma RS (2017) Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discov Today 22:1224–1232. https://doi.org/10.1016/j.drudis.2017.05.006
Beloqui A, Memvanga PB, Coco R, Reimondez-Troitino S, Alhouayek M, Muccioli GG, Alonso MJ, Csaba N, de la Fuente M, Preat V (2016) A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease. Colloids Surf B 143:327–335. https://doi.org/10.1016/j.colsurfb.2016.03.038
Byeon JC, Ahn JB, Jang WS, Lee S-E, Choi J-S, Park J-S (2019) Recent formulation approaches to oral delivery of herbal medicines. J Pharm Investig 49:17–26. https://doi.org/10.1007/s40005-018-0394-4
Chen WL, Yuan ZQ, Liu Y, Yang SD, Zhang CG, Li JZ, Zhu WJ, Li F, Zhou XF, Lin YM, Zhang XN (2016) Liposomes coated with N-trimethyl chitosan to improve the absorption of harmine in vivo and in vitro. Int J Nanomed 11:325–336. https://doi.org/10.2147/IJN.S95540
Choi YH, Han H-K (2018) Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Investig 48:43–60. https://doi.org/10.1007/s40005-017-0370-4
Choi JS, Cao J, Naeem M, Noh J, Hasan N, Choi HK, Yoo JW (2014) Size-controlled biodegradable nanoparticles: preparation and size-dependent cellular uptake and tumor cell growth inhibition. Colloids Surf B 122:545–551. https://doi.org/10.1016/j.colsurfb.2014.07.030
Collnot EM, Ali H, Lehr CM (2012) Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J Control Release 161:235–246. https://doi.org/10.1016/j.jconrel.2012.01.028
Cone RA (2009) Barrier properties of mucus. Adv Drug Deliv Rev 61:75–85. https://doi.org/10.1016/j.addr.2008.09.008
Crater JS, Carrier RL (2010) Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol Biosci 10:1473–1483. https://doi.org/10.1002/mabi.201000137
Cunningham D, Atkin W, Lenz H, Lynch H, Minsky B, Nordlinger B (2010) Colorectal cancer. Lancet 375:1030–1047. https://doi.org/10.1016/S0140-6736(10)60353-4
Deng Z, Rong Y, Teng Y, Mu J, Zhuang X, Tseng M, Samykutty A, Zhang L, Yan J, Miller D, Suttles J, Zhang HG (2017) Broccoli-derived nanoparticle inhibits mouse colitis by activating dendritic cell AMP-activated protein kinase. Mol Ther 25:1641–1654. https://doi.org/10.1016/j.ymthe.2017.01.025
Dianzani C, Foglietta F, Ferrara B, Rosa AC, Muntoni E, Gasco P, Della Pepa C, Canaparo R, Serpe L (2017) Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model. World J Gastroenterol 23:4200–4210. https://doi.org/10.3748/wjg.v23.i23.4200
Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, BÜSCHENFELDE KHMZ (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102:448–455. https://doi.org/10.1111/j.1365-2249.1995.tb03836.x
Dutta D, Chakraborty A, Mukherjee B, Gupta S (2018) Aptamer-conjugated apigenin nanoparticles to target colorectal Carcinoma: A promising safe alternative of colorectal cancer chemotherapy. ACS Appl Bio Mater 1:1538–1556. https://doi.org/10.1021/acsabm.8b00441
Elmowafy EM, Tiboni M, Soliman ME (2019) Biocompatibility, biodegradation and biomedical applications of poly (lactic acid)/poly (lactic-co-glycolic acid) micro and nanoparticles. J. Pharm. Investig. https://doi.org/10.1007/s40005-019-00439-x
Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN (1993) Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci 38:1989–1993. https://doi.org/10.1007/bf01297074
Farris E, Brown DM, Ramer-Tait AE, Pannier AK (2017) Chitosan-zein nano-in-microparticles capable of mediating in vivo transgene expression following oral delivery. J Control Release 249:150–161. https://doi.org/10.1016/j.jconrel.2017.01.035
Frede A, Neuhaus B, Klopfleisch R, Walker C, Buer J, Müller W, Epple M, Westendorf AM (2016) Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo. J Control Release 222:86–96. https://doi.org/10.1016/j.jconrel.2015.12.021
Garza-Treviño EN, Said-Fernández SL, Martínez-Rodríguez HG (2015) Understanding the colon cancer stem cells and perspectives on treatment. Cancer Cell Int 15:2. https://doi.org/10.1186/s12935-015-0163-7
Ghosh D, Peng X, Leal J, Mohanty RP (2018) Peptides as drug delivery vehicles across biological barriers. J Pharm Investig 48:89–111. https://doi.org/10.1007/s40005-017-0374-0
Goodrich GP, Bao L, Gill-Sharp KL, Sang KL, Wang JC, Payne JD (2010) Photothermal therapy in a murine colon cancer model using near-infrared absorbing gold nanorods. J Biomed Optics 15:018001. https://doi.org/10.1117/1.3290817
Griffiths PC, Cattoz B, Ibrahim MS, Anuonye JC (2015) Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering. Eur J Pharm Biopharm 97:218–222. https://doi.org/10.1016/j.ejpb.2015.05.004
Gugulothu D, Kulkarni A, Patravale V, Dandekar P (2014) pH-sensitive nanoparticles of curcumin–celecoxib combination: evaluating drug synergy in ulcerative colitis model. J Pharm Sci 103:687–696. https://doi.org/10.1002/jps.23828
Hebden JA, Blackshaw P, Perkins A, Wilson C, Spiller R (2000) Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 14:155–162
Homayun B, Kumar A, Nascimento PT, Choi H-J (2018) Macropored microparticles with a core–shell architecture for oral delivery of biopharmaceuticals. Arch Pharm Res 41:848–860. https://doi.org/10.1007/s12272-018-1062-y
Hu Z, Mawatari S, Shibata N, Takada K, Yoshikawa H, Arakawa A, Yosida Y (2000) Application of a biomagnetic measurement system (BMS) to the evaluation of gastrointestinal transit of intestinal pressure-controlled colon delivery capsules (PCDCs) in human subjects. Pharm Res 17:160–167. https://doi.org/10.1023/a:1007561129221
Hua S (2014) Orally administered liposomal formulations for colon targeted drug delivery. Front Pharmacol 5:138. https://doi.org/10.3389/fphar.2014.00138
Hua S, Marks E, Schneider JJ, Keely S (2015) Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine 11:1117–1132. https://doi.org/10.1016/j.nano.2015.02.018
Imperiale JC, Sosnik A (2013) Nanoparticle-in-Microparticle delivery systems (NiMDS): production, administration routes and clinical potential. J Biomater Tissue Eng 3:22–38. https://doi.org/10.1016/j.actbio.2018.04.045
Irrazábal T, Belcheva A, Girardin SE, Martin A, Philpott DJ (2014) The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell 54:309–320. https://doi.org/10.1016/j.molcel.2014.03.039
Jain SK, Tiwari A, Jain A, Verma A, Saraf S, Panda PK, Gour G (2018) Application potential of polymeric nanoconstructs for colon-specific drug delivery. In: Barkat M, Beg S, Ahmad FJ (eds) Multifunctional nanocarriers for contemporary healthcare applications. IGI Global, Hershey, pp 22–49. https://doi.org/10.4018/978-1-5225-4781-5.ch002
Jeon G, Ko YT (2019) Enhanced photodyamic therapy via photosensitizer-loaded nanoparticles for cancer treatment. J Pharm Investig 49:1–8. https://doi.org/10.1007/s40005-017-0363-3
Ji C, Xu H, Wu W (2007) In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of indomethacin. J Drug Target 15:123–131. https://doi.org/10.1080/10611860601143727
Johansson ME, Ambort D, Pelaseyed T, Schutte A, Gustafsson JK, Ermund A, Subramani DB, Holmen-Larsson JM, Thomsson KA, Bergstrom JH, van der Post S, Rodriguez-Pineiro AM, Sjovall H, Backstrom M, Hansson GC (2011) Composition and functional role of the mucus layers in the intestine. Cell Mol Life Sci 68:3635–3641. https://doi.org/10.1007/s00018-011-0822-3
Ju S, Mu J, Dokland T, Zhuang X, Wang Q, Jiang H, Xiang X, Deng ZB, Wang B, Zhang L, Roth M, Welti R, Mobley J, Jun Y, Miller D, Zhang HG (2013) Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol Ther 21:1345–1357. https://doi.org/10.1038/mt.2013.64
Kane S, Huo D, Aikens J, Hanauer S (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114:39–43. https://doi.org/10.1016/s0002-9343(02)01383-9
Kesisoglou F, Zhou SY, Niemiec S, Lee JW, Zimmermann EM, Fleisher D (2005) Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model. Pharm Res 22:1320–1330. https://doi.org/10.1007/s11095-005-5376-3
Kim W, Lee Y, Jeong S, Nam J, Lee S, Jung Y (2015) Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent. Arch Pharm Res 38:1830–1838. https://doi.org/10.1007/s12272-015-0602-y
Kim JH, Shin DH, Kim JS (2018) Preparation, characterization, and pharmacokinetics of liposomal docetaxel for oral administration. Arch Pharm Res 41:765–775. https://doi.org/10.1007/s12272-018-1046-y
Klotz U, Schwab M (2005) Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 57:267–279. https://doi.org/10.1016/j.addr.2004.08.007
Kotelevets L, Chastre E, Desmaele D, Couvreur P (2016) Nanotechnologies for the treatment of colon cancer: From old drugs to new hope. Int J Pharm 514:24–40. https://doi.org/10.1016/j.ijpharm.2016.06.005
Kotla NG, Rana S, Sivaraman G, Sunnapu O, Vemula PK, Pandit A, Rochev Y (2019) Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives. Adv Drug Deliv Rev 146:248–266. https://doi.org/10.1016/j.addr.2018.06.021
Koziolek M, Grimm M, Becker D, Iordanov V, Zou H, Shimizu J, Wanke C, Garbacz G, Weitschies W (2015) Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the Intellicap® system. J Pharm Sci 104:2855–2863. https://doi.org/10.1002/jps.24274
Lai SK, Wang YY, Hanes J (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61:158–171. https://doi.org/10.1016/j.addr.2008.11.002
Lamprecht A, Schafer U, Lehr CM (2001) Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 18:788–793. https://doi.org/10.1023/a:1011032328064
Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y (2005) Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharm Exp Ther 315:196–202. https://doi.org/10.1124/jpet.105.088146
Lautenschläger C, Schmidt C, Fischer D, Stallmach A (2014) Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev 71:58–76. https://doi.org/10.1016/j.addr.2013.10.001
Lee JY (2018) Anti-inflammatory effects of sinapic acid on 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice. Arch Pharm Res 41:243–250. https://doi.org/10.1007/s12272-018-1006-6
Lee YS, Johnson PJ, Robbins PT, Bridson RH (2013) Production of nanoparticles-in-microparticles by a double emulsion method: a comprehensive study. Eur J Pharm Biopharm 83:168–173. https://doi.org/10.1016/j.ejpb.2012.10.016
Li L, Ahmed B, Mehta K, Kurzrock R (2007) Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 6:1276–1282. https://doi.org/10.1158/1535-7163.MCT-06-0556
Lieleg O, Vladescu I, Ribbeck K (2010) Characterization of particle translocation through mucin hydrogels. Biophys J 98:1782–1789. https://doi.org/10.1016/j.bpj.2010.01.012
Ling K, Wu H, Neish AS, Champion JA (2019) Alginate/chitosan microparticles for gastric passage and intestinal release of therapeutic protein nanoparticles. J Control Release 295:174–186. https://doi.org/10.1016/j.jconrel.2018.12.017
Ma X, Williams RO (2018) Polymeric nanomedicines for poorly soluble drugs in oral delivery systems: an update. J Pharm Investig 48:61–75. https://doi.org/10.1007/s40005-017-0372-2
Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H (2013) Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS ONE 8:e53916. https://doi.org/10.1371/journal.pone.0053916
Ma Y, Fuchs AV, Boase NR, Rolfe BE, Coombes AG, Thurecht KJ (2015) The in vivo fate of nanoparticles and nanoparticle-loaded microcapsules after oral administration in mice: evaluation of their potential for colon-specific delivery. Eur J Pharm Biopharm 94:393–403. https://doi.org/10.1016/j.ejpb.2015.06.014
Maisel K, Ensign L, Reddy M, Cone R, Hanes J (2015) Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J Control Release 197:48–57. https://doi.org/10.1016/j.jconrel.2014.10.026
Makhlof A, Tozuka Y, Takeuchi H (2009) pH-sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm 72:1–8. https://doi.org/10.1016/j.ejpb.2008.12.013
Malayandi R, Kondamudi PK, Ruby PK, Aggarwal D (2014) Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv Transl Res 4:187–202. https://doi.org/10.1007/s13346-013-0185-4
Matsuda K-I, Takaya T, Shimoji F, Muraoka M, Yoshikawa Y, Takada K (1996) Effect of food intake on the delivery of fluorescein as a model drug in colon delivery capsule after oral administration to beagle dogs. J Drug Target 4:59–67. https://doi.org/10.3109/10611869609046263
McConnell EL, Fadda HM, Basit AW (2008a) Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm 364:213–226. https://doi.org/10.1016/j.ijpharm.2008.05.012
McConnell EL, Short MD, Basit AW (2008b) An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man. J Control Release 130:154–160. https://doi.org/10.1016/j.jconrel.2008.05.022
Melero A, Draheim C, Hansen S, Giner E, Carreras JJ, Talens-Visconti R, Garrigues TM, Peris JE, Recio MC, Giner R, Lehr CM (2017) Targeted delivery of cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. Eur J Pharm Biopharm 119:361–371. https://doi.org/10.1016/j.ejpb.2017.07.004
Molodecky NA, Kaplan GG (2010) Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 6:339–346
Moulari B, Pertuit D, Pellequer Y, Lamprecht A (2008) The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials 29:4554–4560. https://doi.org/10.1016/j.biomaterials.2008.08.009
Mrsny RJ (2012) Oral drug delivery research in Europe. J Control Release 161:247–253. https://doi.org/10.1016/j.jconrel.2012.01.017
Naeem M, Cao J, Choi M, Kim WS, Moon HR, Lee BL, Kim MS, Jung Y, Yoo JW (2015a) Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles. Int J Nanomed 10:4565–4580. https://doi.org/10.2147/IJN.S87816
Naeem M, Choi M, Cao J, Lee Y, Ikram M, Yoon S, Lee J, Moon HR, Kim M-S, Jung Y (2015b) Colon-targeted delivery of budesonide using dual pH-and time-dependent polymeric nanoparticles for colitis therapy. Drug Des Dev Ther 9:3789. https://doi.org/10.2147/DDDT.S88672
Naeem M, Bae J, Oshi MA, Kim M-s, Moon HR, Lee BL, Im E, Jung Y, Yoo J-W (2018a) Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int J Nanomed 13:1225. https://doi.org/10.2147/IJN.S157566
Naeem M, Oshi MA, Kim J, Lee J, Cao J, Nurhasni H, Im E, Jung Y, Yoo JW (2018b) pH-triggered surface charge-reversal nanoparticles alleviate experimental murine colitis via selective accumulation in inflamed colon regions. Nanomedicine 14:823–834. https://doi.org/10.1016/j.nano.2018.01.003
Nance EA, Woodworth GF, Sailor KA, Shih T-Y, Xu Q, Swaminathan G, Xiang D, Eberhart C, Hanes J (2012) A dense poly (ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Trans Med 4:149ra119–149ra119. https://doi.org/10.1126/scitranslmed.3003594
Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV Jr, Tysk C, O'Morain C, Moum B, Colombel JF (2013) Epidemiology, natural history task force of the international organization of inflammatory bowel disease. Gut 62:630–649. https://doi.org/10.1136/gutjnl-2012-303661
Niebel W, Walkenbach K, Beduneau A, Pellequer Y, Lamprecht A (2012) Nanoparticle-based clodronate delivery mitigates murine experimental colitis. J Control Release 160:659–665. https://doi.org/10.1016/j.jconrel.2012.03.004
Ortiz R, Prados J, Melguizo C, Arias JL, Ruiz MA, Álvarez PJ, Caba O, Luque R, Segura A, Aránega A (2012) 5-Fluorouracil-loaded poly (ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer. Int J Nanomed 7:95. https://doi.org/10.2147/IJN.S26401
Oshi MA, Naeem M, Bae J, Kim J, Lee J, Hasan N, Kim W, Im E, Jung Y, Yoo JW (2018) Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydr Polym 198:434–442. https://doi.org/10.1016/j.carbpol.2018.06.107
Patel MM, Amin AF (2011) Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer. Drug Deliv 18:281–293. https://doi.org/10.3109/10717544.2010.538447
Patil SC, Tagalpallewar AA, Kokare CR (2019) Natural anti-proliferative agent loaded self-microemulsifying nanoparticles for potential therapy in oral squamous carcinoma. J Pharm Investig 49:527–541. https://doi.org/10.1007/s40005-018-00415-x
Pelaseyed T, Bergstrom JH, Gustafsson JK, Ermund A, Birchenough GM, Schutte A, van der Post S, Svensson F, Rodriguez-Pineiro AM, Nystrom EE, Wising C, Johansson ME, Hansson GC (2014) The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev 260:8–20. https://doi.org/10.1111/imr.12182
Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaili L, Refouvelet B, Pellequer Y, Lamprecht A (2007) 5-Amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release 123:211–218. https://doi.org/10.1016/j.jconrel.2007.08.008
Piechota-Polanczyk A, Fichna J (2014) Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch Pharmacol 387:605–620. https://doi.org/10.1007/s00210-014-0985-1
Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S (2019) Environmental Risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology 157(647–659):e644. https://doi.org/10.1053/j.gastro.2019.04.016
Ponchel G, Irache J (1998) Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev 34:191–219. https://doi.org/10.1016/s0169-409x(98)00040-4
Pool H, Campos-Vega R, Herrera-Hernandez MG, Garcia-Solis P, Garcia-Gasca T, Sanchez IC, Luna-Barcenas G, Vergara-Castaneda H (2018) Development of genistein-PEGylated silica hybrid nanomaterials with enhanced antioxidant and antiproliferative properties on HT29 human colon cancer cells. Am J Transl Res 10:2306–2323
Prajakta D, Ratnesh J, Chandan K, Suresh S, Grace S, Meera V, Vandana P (2009) Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J Biomed Nanotechnol 5:445–455. https://doi.org/10.1166/jbn.2009.1038
Qiao H, Fang D, Chen J, Sun Y, Kang C, Di L, Li J, Chen Z, Chen J, Gao Y (2017) Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. Drug Deliv 24:233–242. https://doi.org/10.1080/10717544.2016.1245367
Qin X (2012) Etiology of inflammatory bowel disease: a unified hypothesis. World J Gastroenterol 18:1708–1722. https://doi.org/10.3748/wjg.v18.i15.1708
Quesenberry PJ, Aliotta J, Camussi G, Abdel-Mageed AB, Wen S, Goldberg L, Zhang HG, Tetta C, Franklin J, Coffey RJ, Danielson K, Subramanya V, Ghiran I, Das S, Chen CC, Pusic KM, Pusic AD, Chatterjee D, Kraig RP, Balaj L, Dooner M (2015) Potential functional applications of extracellular vesicles: a report by the NIH Common Fund Extracellular RNA Communication Consortium. J Extracell Vesicles 4:27575. https://doi.org/10.3402/jev.v4.27575
Raj PM, Raj R, Kaul A, Mishra AK, Ram A (2018) Biodistribution and targeting potential assessment of mucoadhesive chitosan nanoparticles designed for ulcerative colitis via scintigraphy. RSC Adv 8:20809–20821
Ramadan AA, Elbakry AM, Esmaeil AH, Khaleel SA (2018) Pharmaceutical and pharmacokinetic evaluation of novel rectal mucoadhesive hydrogels containing tolmetin sodium. J Pharm Investig 48:673–683. https://doi.org/10.1007/s40005-017-0365-1
Rao K, Yazaki E, Evans D, Carbon R (2004) Objective evaluation of small bowel and colonic transit time using pH telemetry in athletes with gastrointestinal symptoms. Br J Sports Med 38:482–487. https://doi.org/10.1136/bjsm.2003.006825
Reineke JJ, Cho DY, Dingle Y-T, Morello AP, Jacob J, Thanos CG, Mathiowitz E (2013) Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres. Proc Natl Acad Sci 110:13803–13808
Rhodes JM, Campbell BJ (2002) Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med 8:10–16. https://doi.org/10.1016/s1471-4914(01)02194-3
Rizzello F, Gionchetti P, D'Arienzo A, Manguso F, Di Matteo G, Annese V, Valpiani D, Casetti T, Adamo S, Prada A, Castiglione GN, Varoli G, Campieri M (2002) Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 16:1109–1116. https://doi.org/10.1046/j.1365-2036.2002.01298.x
Ruttala HB, Ramasamy T, Madeshwaran T, Hiep TT, Kandasamy U, Oh KT, Choi HG, Yong CS, Kim JO (2018) Emerging potential of stimulus-responsive nanosized anticancer drug delivery systems for systemic applications. Arch Pharm Res 41:111–129. https://doi.org/10.1007/s12272-017-0995-x
Saleh M, Trinchieri G (2011) Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 11:9–20. https://doi.org/10.1038/nri2891
Sandborn WJ (2010) Therapeutic approaches to the treatment of ulcerative colitis. In: Targan SR, Shanahan F, Karp LC (eds) Inflammatory bowel disease: translating basic science into clinical practice. Wiley-Blackwell, Chichester, pp 415–443
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H (2014) Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J Gastroenterol 20:9699. https://doi.org/10.3748/wjg.v20.i29.9699
Sheng J, Han L, Qin J, Ru G, Li R, Wu L, Cui D, Yang P, He Y, Wang J (2015) N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption. ACS Appl Mater Interfaces 7:15430–15441. https://doi.org/10.1021/acsami.5b03555
Shi L-L, Xie H, Lu J, Cao Y, Liu J-Y, Zhang X-X, Zhang H, Cui J-H, Cao Q-R (2016) Positively charged surface-modified solid lipid nanoparticles promote the intestinal transport of docetaxel through multifunctional mechanisms in rats. Mol Pharm 13:2667–2676. https://doi.org/10.1021/acs.molpharmaceut.6b00226
Si XY, Merlin D, Xiao B (2016) Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease. World J Gastroenterol 22:7718–7726. https://doi.org/10.3748/wjg.v22.i34.7718
Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics. CA Cancer J Clin 64:104–117. https://doi.org/10.3322/caac.21220
Sim T, Lim C, Hoang NH, Joo H, Lee JW, Kim D-W, Lee ES, Youn YS, Kim JO, Oh KT (2016) Nanomedicines for oral administration based on diverse nanoplatform. J Pharm Investig 46:351–362. https://doi.org/10.1007/s40005-016-0255-y
Simmonds NJ, Allen RE, Stevens TR, Van Someren RN, Blake DR, Rampton DS (1992) Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 103:186–196. https://doi.org/10.1016/0016-5085(92)91112-h
Sonaje K, Chen YJ, Chen HL, Wey SP, Juang JH, Nguyen HN, Hsu CW, Lin KJ, Sung HW (2010) Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 31:3384–3394. https://doi.org/10.1016/j.biomaterials.2010.01.042
Steed K, Hooper G, Monti N, Benedetti MS, Fornasini G, Wilding I (1997) The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system (“TIME CLOCK®” system). J Control Release 49:115–122. https://doi.org/10.1016/S0168-3659(97)00062-X
Tahara K, Samura S, Tsuji K, Yamamoto H, Tsukada Y, Bando Y, Tsujimoto H, Morishita R, Kawashima Y (2011) Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly (D, L-lactide-co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials 32:870–878. https://doi.org/10.1016/j.biomaterials.2010.09.034
Talaei F, Atyabi F, Azhdarzadeh M, Dinarvand R, Saadatzadeh A (2013) Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies. Eur J Pharm Sci 49:712–722. https://doi.org/10.1016/j.ejps.2013.04.031
Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P, American College of Gastroenterology IBDTF (2011) An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 106(Suppl 1):S2–25. https://doi.org/10.1038/ajg.2011.58 quiz S26
Tang BC, Dawson M, Lai SK, Wang Y-Y, Suk JS, Yang M, Zeitlin P, Boyle MP, Fu J, Hanes J (2009) Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci 106:19268–19273. https://doi.org/10.1073/pnas.0905998106
Testa A, Castiglione F, Nardone OM, Colombo GL (2017) Adherence in ulcerative colitis: an overview. Patient Prefer Adherence 11:297–303. https://doi.org/10.2147/PPA.S127039
Thapaliya R, Shrestha K, Sharma A, Dhakal N, Manandhar P, Shrestha S, Bhattarai R (2019) Physicochemical characterization of naproxen microcrystals for colon specific pulsatile drug delivery designed using pulsincap technique. J Pharm Investig. https://doi.org/10.1007/s40005-019-00425-3
Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP (2015) Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350:g7607. https://doi.org/10.1136/bmj.g7607
Tummala S, Satish Kumar MN, Prakash A (2015) Formulation and characterization of 5-fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J 23:308–314. https://doi.org/10.1016/j.jsps.2014.11.010
Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816. https://doi.org/10.1053/j.gastro.2011.01.057
Vong LB, Tomita T, Yoshitomi T, Matsui H, Nagasaki Y (2012) An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice. Gastroenterology 143:1027–1036. https://doi.org/10.1053/j.gastro.2012.06.043
Vong LB, Mo J, Abrahamsson B, Nagasaki Y (2015a) Specific accumulation of orally administered redox nanotherapeutics in the inflamed colon reducing inflammation with dose–response efficacy. J Control Release 210:19–25. https://doi.org/10.1016/j.jconrel.2015.05.275
Vong LB, Yoshitomi T, Matsui H, Nagasaki Y (2015b) Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer. Biomaterials 55:54–63. https://doi.org/10.1016/j.biomaterials.2015.03.037
Wang Q, Zhuang X, Mu J, Deng Z-B, Jiang H, Zhang L, Xiang X, Wang B, Yan J, Miller D (2013) Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. Nat Commun 4:1867. https://doi.org/10.1038/ncomms2886
Williams BA, Grant LJ, Gidley MJ, Mikkelsen D (2017) Gut Fermentation of Dietary Fibres: Physico-Chemistry of Plant Cell Walls and Implications for Health. Int J Mol Sci 18:2203. https://doi.org/10.3390/ijms18102203
Xiao B, Merlin D (2012) Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin Drug Deliv 9:1393–1407. https://doi.org/10.1517/17425247.2012.730517
Xiao B, Si X, Han MK, Viennois E, Zhang M, Merlin D (2015) Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. J Mater Chem B 3:7724–7733. https://doi.org/10.1039/c5tb01245g
Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D (2017) Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther 25:1628–1640. https://doi.org/10.1016/j.ymthe.2016.11.020
Yang C, Merlin D (2019) Nanoparticle-mediated drug delivery systems for the treatment of IBD: current perspectives. Int J Nanomed 14:8875–8889. https://doi.org/10.2147/IJN.S210315
Yassin AE, Anwer MK, Mowafy HA, El-Bagory IM, Bayomi MA, Alsarra IA (2010) Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci 7:398–408. https://doi.org/10.7150/ijms.7.398
You X, Kang Y, Hollett G, Chen X, Zhao W, Gu Z, Wu J (2016) Polymeric nanoparticles for colon cancer therapy: overview and perspectives. J Mater Chem B 4:7779–7792. https://doi.org/10.1039/c6tb01925k
Zeeshan M, Ali H, Khan S, Khan SA, Weigmann B (2019) Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease. Int J Pharm 558:201–214. https://doi.org/10.1016/j.ijpharm.2018.12.074
Zhang M, Merlin D (2018) Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. Inflamm Bowel Dis 24:1401–1415. https://doi.org/10.1093/ibd/izy123
Zhang L, Sang Y, Feng J, Li Z, Zhao A (2016a) Polysaccharide-based micro/nanocarriers for oral colon-targeted drug delivery. J Drug Target 24:579–589. https://doi.org/10.3109/1061186X.2015.1128941
Zhang M, Viennois E, Prasad M, Zhang Y, Wang L, Zhang Z, Han MK, Xiao B, Xu C, Srinivasan S, Merlin D (2016b) Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials 101:321–340. https://doi.org/10.1016/j.biomaterials.2016.06.018
Zhang M, Xiao B, Wang H, Han MK, Zhang Z, Viennois E, Xu C, Merlin D (2016c) Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy. Mol Ther 24:1783–1796. https://doi.org/10.1038/mt.2016.159
Zhang Q, Tao H, Lin Y, Hu Y, An H, Zhang D, Feng S, Hu H, Wang R, Li X, Zhang J (2016d) A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease. Biomaterials 105:206–221. https://doi.org/10.1016/j.biomaterials.2016.08.010
Zhang M, Wang X, Han MK, Collins JF, Merlin D (2017) Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis. Nanomedicine 12:1927–1943. https://doi.org/10.2217/nnm-2017-0196
Acknowledgements
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), and funded by the Ministry of Education (Grant Number: NRF-2019R1I1A3A01057849).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Naeem, M., Awan, U.A., Subhan, F. et al. Advances in colon-targeted nano-drug delivery systems: challenges and solutions. Arch. Pharm. Res. 43, 153–169 (2020). https://doi.org/10.1007/s12272-020-01219-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-020-01219-0